March 2012 Issue of MMM
March 2012 issue
Researchers are sensing a waning influence within their companies
James Chase asked 16 of last year's judges about how entrants can improve their chances of winning an MM&M Award
Market research must transform itself or run the risk of becoming obsolete. Marc Iskowitz teams with the PMRG and TGaS Advisors to review the cold ...
Specialty biopharma firms are using razor-sharp therapeutic focus to target "niche buster" categories.
Co-pay cards have proliferated, undermining payer benefit plans. Now, insurers are striking back against the cards.
It was a night to remember as the stars of medical advertising came out to welcome three more legends into the Hall of Fame
Jeff Arnold, co-founder, chairman and CEO, Sharecare
Social media can have a far-reaching impact on study time, costs, quality and outcomes
Counterfeiters are making a version of Avastin that lacks the drug's main active ingredient
Why the Susan G. Komen for the Cure Foundation's previously unassailable brand in healthcare fundraising may have sustained some permanent damage.
AstraZeneca confirmed rumors of another round of deep cuts, announcing that it will eliminate 7,300 positions.
The U.S. Solicitor General has filed an amicus brief taking the side of two pharmaceutical sales reps in the overtime case that they filed against ...
News on D&R Communications, Publicis Touchpoint Solutions, Santarus and Physicians Interactive
Med Ed Report
Allergan removed some doctor-payment records from its website that the drugmaker had posted from 2010-2011 as a result of a Botox legal settlement.
About 65% of the 1,800 physicians surveyed in a 2009 study discussed in Health Affairs support disclosing potential conflicts of interest to patients.
Progress in keeping commercial bias from industry-based certified CME is at hand, say those who produce and fund it.
News on FDA, Med-IQ, the American Medical Student Association, Best Practices, the American College of Physicians and CECity
An online protest has pulled the scientific publishing industry, and particularly Dutch publisher Elsevier, into a tug of war with writers.
Glenn Kolansky, Board Certified Dermatologist, Adv. Dermatology Surgery & Laser Center, Red Bank, NJ.
Open-access research project F1000 has launched a program in which submissions are published following an "initial sanity check" from the project's director of new product ...
News about Jobson Medical Information Holdings, Medical Prescribing Reference, DTW Research Marketing Group and Communications Media Inc./Compas
Missing documents allegedly kept a review of Tamiflu from conclusively examining the drug's efficacy. Are reviews marred by publication and reporting biases? What can be ...
Weary of FDA foot-dragging on digital and social media guidance for pharmas, a group of industry digerati put together guidelines of their own.
P&G has historically spent 9%-11% on advertising, but the company is looking for corners to cut and finding them in social media.
News about AstraZeneca, Everyday Health and the AMA
An FDA study on the power of background visuals found no evidence that consumer understanding of risk info is affected by the "emotional (affective) tone ...
Two brands are fighting for attention from OAB sufferers: GSK-Astellas's Vesicare and Pfizer's Toviaz. Their DTC approaches couldn't be more different.
J&J named Roberto Marques to serve as the company group chairman responsible for the recall-plagued McNeil Consumer Healthcare unit
The Physician Payment Sunshine Act maintains the exclusion for marketing research incentives
Market research firm Pharmafakt GFD is accused of selling prescription info without removing data that can be used to trace identities.
McCann HumanCare landed the agency of record assignment for consumer advertising and communications on Merck's respiratory franchise
MSLGroup Americas named Unilever's Janelle Dixon SVP director of insights creation and measurement.
News about Ogilvy CommonHealth Worldwide, Draftfcb, D&R Communications, Moroney & Gill
It's time for a regulatory Marshall plan to help build global systems for quality and safety
U.S. senators Amy Klobuchar and Susan Collins are trying to quickly pass a bill addressing the growing drug shortage problem
Congressional inaction could lead to a huge new products-review backlog, according to FDA Matters editor Steven Grossman.
What happens when a celebrity goes off message, gets a DUI or is photographed eating a hamburger?
Consumer work that creatively breaks the healthcare barriers and, most importantly, drives customers to act
At Work With
Marsha Braverman, Exec. Dir. of Marketing & Communications, Drexel Univ. College of Medicine
Chris Guiffre, SVP and Chief Business Officer, Cerulean Pharmaceuticals
Manufacurer and agency hires and promotions
Name That Brand
This first-to-market drug's campaign asks consumers why they want to increase their chances of being cured.
The desire to reduce the cost of delivering care has led to redefining 'point of care'
- Biogen ends Tecfidera DTC campaign, citing prescriptions
- Five things for pharma marketers to know: Tuesday, July 19, 2016
- Five things for pharma marketers to know: Monday, July 18, 2016
- Five things for pharma marketers to know: Thursday, July 21, 2016
- Five things for pharma marketers to know: Wednesday, July 20, 2016
- Merck educates doctors about biosimilars, long before it will sell one in the U.S.
- 4 trends with the potential to change behavior in the patient journey
- 2016 Pharma Report: All the data in one place
- What do physicians think about biosimilars?
- Novartis considers new sales model for experimental cancer therapy